190 related articles for article (PubMed ID: 38127586)
21. Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A.
Wang CP; Young G; Thornburg CD
Expert Opin Drug Saf; 2021 Apr; 20(4):387-396. PubMed ID: 33612049
[TBL] [Abstract][Full Text] [Related]
22. Emicizumab for hemophilia A without inhibitors.
Cafuir L; Kruse-Jarres R; Mancuso ME; Kempton CL
Expert Rev Hematol; 2019 Jul; 12(7):515-524. PubMed ID: 31130012
[No Abstract] [Full Text] [Related]
23. Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.
Schmitt C; Mancuso ME; Chang T; Podolak-Dawidziak M; Petry C; Sidonio R; Yoneyama K; Key NS; Niggli M; Lehle M; Peyvandi F; Oldenburg J
Haemophilia; 2023 Jan; 29(1):90-99. PubMed ID: 36271487
[TBL] [Abstract][Full Text] [Related]
24. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
Kempton C; Trask P; Parnes A; Niggli M; Campinha-Bacote A; U Callaghan M; O'Connell N; Paz-Priel I; Mahlangu JN
Haemophilia; 2021 Mar; 27(2):221-228. PubMed ID: 33506955
[TBL] [Abstract][Full Text] [Related]
25. Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients.
Patil R; Shanmukhaiah C; Gogtay NJ; Pandey P; Patil K; Jijina F; Madkaikar M
J Thromb Haemost; 2024 Apr; 22(4):1024-1030. PubMed ID: 38160726
[TBL] [Abstract][Full Text] [Related]
26. Emicizumab prophylaxis in infants: Single-centre experience.
Levy-Mendelovich S; Greenberg-Kushnir N; Budnik I; Barg AA; Cohen O; Avishai E; Barazani-Brutman T; Livnat T; Kenet G
Br J Haematol; 2024 Apr; 204(4):1375-1382. PubMed ID: 38266507
[TBL] [Abstract][Full Text] [Related]
27. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab.
Bou-Jaoudeh M; Mimoun A; Delignat S; Peyron I; Capdevila L; Daventure V; Deligne C; Dimitrov JD; Christophe OD; Denis CV; Lenting PJ; Proulle V; Lacroix-Desmazes S
J Thromb Haemost; 2023 Oct; 21(10):2776-2783. PubMed ID: 37473843
[TBL] [Abstract][Full Text] [Related]
28. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
29. Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring.
Barg AA; Budnik I; Avishai E; Brutman-Barazani T; Bashari D; Misgav M; Lubetsky A; Kuperman AA; Livnat T; Kenet G
Haemophilia; 2021 May; 27(3):383-391. PubMed ID: 33892524
[TBL] [Abstract][Full Text] [Related]
30. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.
Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M
Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468
[TBL] [Abstract][Full Text] [Related]
31. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T
Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595
[TBL] [Abstract][Full Text] [Related]
32. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
Skinner MW; Négrier C; Paz-Priel I; Chebon S; Jiménez-Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A; Shima M; Campinha-Bacote A; Levy GG; Oldenburg J; von Mackensen S; Pipe SW
Haemophilia; 2021 Sep; 27(5):854-865. PubMed ID: 34171159
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacology of emicizumab for the treatment of hemophilia A.
Yoneyama K; Schmitt C; Portron A; Kiialainen A; Kotani N; Jaminion F; Retout S; Adamkewicz JI
Expert Rev Clin Pharmacol; 2023; 16(9):775-790. PubMed ID: 37529848
[TBL] [Abstract][Full Text] [Related]
34. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors.
Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL
J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
36. AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.
Matsushita T; Suzuki N; Nagao A; Nagae C; Yamaguchi-Suita H; Kyogoku Y; Ioka A; Nogami K
BMJ Open; 2022 Mar; 12(3):e057018. PubMed ID: 35288393
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
[TBL] [Abstract][Full Text] [Related]
38. AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab - protocol for a multicentre, open-label, phase IV clinical study.
Shima M; Takedani H; Kitsukawa K; Taki M; Ishiguro A; Nagao A; Yamaguchi-Suita H; Kyogoku Y; Yoshida S; Nogami K
BMJ Open; 2022 Jun; 12(6):e059667. PubMed ID: 35697445
[TBL] [Abstract][Full Text] [Related]
39. Emicizumab for the treatment of acquired hemophilia A.
Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
[TBL] [Abstract][Full Text] [Related]
40. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.
Ebbert PT; Xavier F; Seaman CD; Ragni MV
Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
